Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy.
<h4>Background</h4> <p>Radiotherapy is an effective treatment of intermediate/high-risk locally advanced prostate cancer, however,>30% of patients relapse within 5 years. Clinicopathological parameters currently fail to identify patients prone to systemic relapse and those...
| Үндсэн зохиолчид: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Journal article |
| Хэл сонгох: | English |
| Хэвлэсэн: |
Oxford University Press
2017
|
| _version_ | 1826302381018578944 |
|---|---|
| author | Jain, S Lyons, C Walker, S McQuaid, S Hynes, S Mitchell, D Pang, B Logan, G McCavigan, A O'Rourke, D McArt, D McDade, S Mills, I Prise, K Knight, L Steele, C Medlow, P Berge, V Katz, B Loblaw, D Harkin, D James, J O'Sullivan, J Kennedy, R Waugh, D |
| author_facet | Jain, S Lyons, C Walker, S McQuaid, S Hynes, S Mitchell, D Pang, B Logan, G McCavigan, A O'Rourke, D McArt, D McDade, S Mills, I Prise, K Knight, L Steele, C Medlow, P Berge, V Katz, B Loblaw, D Harkin, D James, J O'Sullivan, J Kennedy, R Waugh, D |
| author_sort | Jain, S |
| collection | OXFORD |
| description | <h4>Background</h4> <p>Radiotherapy is an effective treatment of intermediate/high-risk locally advanced prostate cancer, however,>30% of patients relapse within 5 years. Clinicopathological parameters currently fail to identify patients prone to systemic relapse and those whom treatment intensification may be beneficial. The purpose of this study was to independently validate the performance of a 70-gene Metastatic Assay in a cohort of diagnostic biopsies from patients treated with radical radiotherapy and androgen deprivation therapy.</p> <h4>Patients and methods</h4> <p>A bridging cohort of prostate cancer diagnostic biopsy specimens was profiled to enable optimization of the Metastatic Assay threshold before further independent clinical validation in a cohort of diagnostic biopsies from patients treated with radical radiotherapy and androgen deprivation therapy. Multivariable Cox proportional hazard regression analysis was used to assess assay performance in predicting biochemical failure-free survival (BFFS) and metastasis-free survival (MFS).</p> <h4>Results</h4> <p>Gene expression analysis was carried out in 248 patients from the independent validation cohort and the Metastatic Assay applied. Ten-year MFS was 72% for Metastatic Assay positive patients and 94% for Metastatic Assay negative patients [HR¼3.21 (1.35–7.67); P¼0.003]. On multivariable analysis the Metastatic Assay remained predictive for development of distant metastases [HR¼2.71 (1.11–6.63); P¼0.030]. The assay retained independent prognostic performance for MFS when assessed with the Cancer of the Prostate Assessment Score (CAPRA) [HR¼3.23 (1.22–8.59); P¼0.019] whilst CAPRA itself was not significant [HR¼1.88, (0.52–6.77); P¼0.332]. A high concordance [100% (61.5–100)] for the assay result was noted between two separate foci taken from 11 tumours, whilst Gleason score had low concordance.</p> <h4>Conclusions</h4> <p>The Metastatic Assay demonstrated significant prognostic performance in patients treated with radical radiotherapy both alone and independent of standard clinical and pathological variables. The Metastatic Assay could have clinical utility when deciding upon treatment intensification in high-risk patients. Genomic and clinical data are available as a public resource.</p> |
| first_indexed | 2024-03-07T05:46:41Z |
| format | Journal article |
| id | oxford-uuid:e774eeba-d558-4bda-b3ae-8261f50cb217 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:46:41Z |
| publishDate | 2017 |
| publisher | Oxford University Press |
| record_format | dspace |
| spelling | oxford-uuid:e774eeba-d558-4bda-b3ae-8261f50cb2172022-03-27T10:38:55ZValidation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:e774eeba-d558-4bda-b3ae-8261f50cb217EnglishSymplectic Elements at OxfordOxford University Press2017Jain, SLyons, CWalker, SMcQuaid, SHynes, SMitchell, DPang, BLogan, GMcCavigan, AO'Rourke, DMcArt, DMcDade, SMills, IPrise, KKnight, LSteele, CMedlow, PBerge, VKatz, BLoblaw, DHarkin, DJames, JO'Sullivan, JKennedy, RWaugh, D <h4>Background</h4> <p>Radiotherapy is an effective treatment of intermediate/high-risk locally advanced prostate cancer, however,>30% of patients relapse within 5 years. Clinicopathological parameters currently fail to identify patients prone to systemic relapse and those whom treatment intensification may be beneficial. The purpose of this study was to independently validate the performance of a 70-gene Metastatic Assay in a cohort of diagnostic biopsies from patients treated with radical radiotherapy and androgen deprivation therapy.</p> <h4>Patients and methods</h4> <p>A bridging cohort of prostate cancer diagnostic biopsy specimens was profiled to enable optimization of the Metastatic Assay threshold before further independent clinical validation in a cohort of diagnostic biopsies from patients treated with radical radiotherapy and androgen deprivation therapy. Multivariable Cox proportional hazard regression analysis was used to assess assay performance in predicting biochemical failure-free survival (BFFS) and metastasis-free survival (MFS).</p> <h4>Results</h4> <p>Gene expression analysis was carried out in 248 patients from the independent validation cohort and the Metastatic Assay applied. Ten-year MFS was 72% for Metastatic Assay positive patients and 94% for Metastatic Assay negative patients [HR¼3.21 (1.35–7.67); P¼0.003]. On multivariable analysis the Metastatic Assay remained predictive for development of distant metastases [HR¼2.71 (1.11–6.63); P¼0.030]. The assay retained independent prognostic performance for MFS when assessed with the Cancer of the Prostate Assessment Score (CAPRA) [HR¼3.23 (1.22–8.59); P¼0.019] whilst CAPRA itself was not significant [HR¼1.88, (0.52–6.77); P¼0.332]. A high concordance [100% (61.5–100)] for the assay result was noted between two separate foci taken from 11 tumours, whilst Gleason score had low concordance.</p> <h4>Conclusions</h4> <p>The Metastatic Assay demonstrated significant prognostic performance in patients treated with radical radiotherapy both alone and independent of standard clinical and pathological variables. The Metastatic Assay could have clinical utility when deciding upon treatment intensification in high-risk patients. Genomic and clinical data are available as a public resource.</p> |
| spellingShingle | Jain, S Lyons, C Walker, S McQuaid, S Hynes, S Mitchell, D Pang, B Logan, G McCavigan, A O'Rourke, D McArt, D McDade, S Mills, I Prise, K Knight, L Steele, C Medlow, P Berge, V Katz, B Loblaw, D Harkin, D James, J O'Sullivan, J Kennedy, R Waugh, D Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy. |
| title | Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy. |
| title_full | Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy. |
| title_fullStr | Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy. |
| title_full_unstemmed | Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy. |
| title_short | Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy. |
| title_sort | validation of a metastatic assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy |
| work_keys_str_mv | AT jains validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT lyonsc validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT walkers validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT mcquaids validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT hyness validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT mitchelld validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT pangb validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT logang validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT mccavigana validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT orourked validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT mcartd validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT mcdades validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT millsi validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT prisek validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT knightl validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT steelec validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT medlowp validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT bergev validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT katzb validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT loblawd validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT harkind validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT jamesj validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT osullivanj validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT kennedyr validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy AT waughd validationofametastaticassayusingbiopsiestoimproveriskstratificationinpatientswithprostatecancertreatedwithradicalradiationtherapy |